Book Chapter

Emerging Methods for Efficient and Extensive Incorporation of Non Canonical Amino Acids using Cell-free Systems

Yang Wu¹,², Zhaoguan Wang¹,², Xin Qiao¹,², Jiaojiao Li¹,², Xiangrong Shu³ and Hao Qi¹,²*¹

¹School of Chemical Engineering and Technology, Tianjin University, China
²Key Laboratory of Systems Bioengineering of Ministry of Education, Tianjin University, China
³Department of Pharmacy, Tianjin Huanhu Hospital, China

*Corresponding Author: Hao Qi, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China

Published December 10, 2020

This Book Chapter is a republication of an article published by Hao Qi, et al. at Frontiers in Bioengineering and Biotechnology in July 2020. (Wu Y, Wang Z, Qiao X, Li J, Shu X and Qi H (2020) Emerging Methods for Efficient and Extensive Incorporation of Non-canonical Amino Acids Using Cell-Free Systems. Front. Bioeng. Biotechnol. 8:863. doi: 10.3389/fbioe.2020.00863)

How to cite this book chapter: Yang Wu, Zhaoguan Wang, Xin Qiao, Jiaojiao Li, Xiangrong Shu, Hao Qi. Emerging Methods for Efficient and Extensive Incorporation of Non Canonical Amino Acids using Cell-free Systems. In: Zahoorullah S MD, editor. Prime Archives in Biotechnology. Hyderabad, India: Vide Leaf. 2020.

© The Author(s) 2020. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflicts of Interest: The authors declare no conflicts of interest.

Author Contributions: YW gathered information, drafted the original manuscript and designed the figures. ZW contributed to literature collection. HQ conceived the presented idea and supervised this work.

Funding: This work was supported by the National Science Foundation of China (Grant Nos. 21476167, 21778039 and 21621004).

Abstract

Cell-free protein synthesis (CFPS) has emerged as a novel protein expression platform. Especially the incorporation of non-canonical amino acids (ncAAs) has led to the development of numerous flexible methods for efficient and extensive expression of artificial proteins. Approaches were developed to eliminate the endogenous competition for ncAAs and engineer translation factors, which significantly enhanced the incorporation efficiency. Furthermore, in vitro aminoacylation methods can be conveniently combined with cell-free systems, extensively expanding the available ncAAs with novel and unique moieties. In this review, we summarize the recent progresses on the efficient and extensive incorporation of ncAAs by different strategies based on the elimination of competition by endogenous factors, translation factors engineering and extensive incorporation of novel ncAAs coupled with in vitro aminoacylation methods in CFPS. We also aim to offer new ideas to researchers working on ncAA incorporation techniques in CFPS and applications in various emerging fields.
Keywords

Cell-Free Synthetic Biology; Cell-Free Protein Synthesis; Non-Canonical Amino Acids; Competition Elimination; In Vitro Aminoacylation

Introduction

Cell-free protein synthesis (CFPS) has emerged as an effective method for the production of recombinant proteins in specialty applications. By eliminating the cell membrane barrier and cell-viability constraint, CFPS offers several benefits over in vivo protein expression [1]. Firstly, with the open nature of CFPS, almost any molecule can be manipulated precisely in the system for different research purposes, especially molecules whose incorporation is limited by inefficient transport across the cell membrane [2]. Secondly, by being able to disregard cell viability, toxic reagents and difficult to express proteins can be employed in CFPS and even some not biocompatible reaction conditions can be applied [3]. Finally, without reproducible cells, biosafety can be guaranteed because artificial genes cannot pollute the environment through cells.

Basically, there are two main CFPS platforms: the PURE system (i.e. protein synthesis using purified recombinant elements), and the cell extract system. In the PURE system, all components of the transcription and translation apparatus are purified from cells individually and assembled into a well-defined CFPS system. Although all components can be defined at precise concentration, the tedious purification steps make the PURE platform much more expensive than the cell extract system [4]. Many efforts have been made recently to reduce the costs and labor, such as one-pot purification methods and purification from fewer fusion plasmids [5-8]. However, partial component control and modularity may be lost in these approaches. The other system relies on non-defined cell extracts. The crude cell extract is separated by lysing cells, so it contains all the native intracellular translation components. Recombinant proteins are synthesized via cell extract based CFPS with the
supplementation of additives, such as energy substrates, NTPs, T7 RNA polymerase, amino acids and salts [9] (Figure 1). Due to the simple preparation, the cell extract platform is much cheaper and convenient. Additionally, with the help of ancillary translational factors in the cell extract, this platform also has higher protein yields [10]. Taken together, both CFPS systems are useful platforms for different applications.

Incorporating nCAs into proteins is an emerging biological research area with fundamental science and engineering benefits. In fundamental science, lots of questions are being answered by nCA techniques, such as labeling proteins by isotopic or fluorescent nCAs, and immobilization of protein using nCAs with special side chains [11]. Post-translational protein modifications (PTM) are difficult to study due to their rapidly shifting levels in the cell. With PTM-mimicking side-chains of nCAs, high amounts of homologous PTM proteins can be synthesized for investigation [12-14]. In engineering applications, a growing number of artificial protein applications are also emerging, including antibody-drug conjugates [15],

Figure 1: Schematic of cell extract based CFPS system preparation and competitors in nCA incorporation. In ribosome, the peptide release factor competes with nCA aminoacyl-tRNA in stop codon reassignment. Endogenous aminoacyl-tRNAs compete with aminoacyl-tRNAs in sense codon reassignment. In aaRS, the canonical amino acid (cAA) may compete with nCA in aminoacylation reaction.
virus-like particle drug conjugates [16], active protein polymers [17], and screening of artificial enzymes [18].

Over 230 ncAAs have been incorporated into proteins by in vivo or in vitro methods [19,20]. In living cells, an orthogonal amino-acyl tRNA synthetase/tRNA (aaRS/tRNA) pair is essential to precisely incorporate ncAAs into proteins. The orthogonality means that aaRS can only incorporate ncAAs at the specific tRNA and the tRNA can only be recognized by a corresponding aaRS [21]. Recently, numerous ncAA aaRS/tRNA pairs were developed based on systems from archaea. For instance, tyrosine derivatives can be installed by *Methanococcus jannaschii* TyrRS/tRNA<sup>Tyr</sup> pair variants and lysine derivatives can be installed by variants of the *Methanosarcina mazei* or *Methanosarcina barkeri* PylRS/tRNA<sup>Pyl</sup> [22]. However, due to great advantages over in vivo research, accelerated studies are concentrating on CFPS to incorporate ncAAs. Firstly, the concentration of ncAA and aaRS/tRNA could be conveniently improved for efficient incorporation without limitation by transport across the cell membrane. Secondly, the negative components, which influence efficient ncAA incorporation, can potentially be eliminated potentially in the open CFPS environment. Thirdly, the subsequent reaction can be performed in situ, avoiding tedious purification from cells [23]. Finally, even toxic ncAAs, which cannot be employed in living cells, could be used in CFPS combined with in vitro aminoacylation methods [24-26]. Therefore, CFPS is a novel platform for ncAA incorporation with great potential.

However, ncAA incorporation in CFPS suffers from endogenous competition (Figure 1). In order to incorporate ncAAs at precise positions, a special codon should be reassigned. Both stop codons and sense codons have been reassigned in various studies [27-29]. There is codon competition between ncAA complexes and endogenous biomolecules, which recognize the codon as a canonical amino acid or translation stop signal, resulting in a truncated or wrong protein instead of the ncAA protein (Figure. 1). Fortunately, various strategies were developed to overcome competition at different levels, fully utilizing the advantages of CFPS [30-32]. We summarize and discuss these efficiency
improvement efforts in this review. In addition to efficient ncAA incorporation, many novel ncAAs can only be used in CFPS using in vitro aminoacylation methods [33-35]. These novel amino acids greatly expand the scope and flexibility of CFPS ncAA incorporation, which is also gaining increasing attention.

The purpose of this review is to give an overview of the emerging methods for improving the scope and efficiency of ncAA incorporation in CFPS. We focus on strategies to raise efficiency at the competition elimination and translation factors engineering. Moreover, the novel ncAAs and in vitro aminoacylation methods, that can only be used in CFPS and expand the range of available ncAAs, are given special attention. This review provides a reference for researchers to choose suitable ncAA incorporation techniques for CFPS and expand the research to more potential fields.

**Strategies for Eliminating Competition**

As shown in Figure 1, the competition for codons, that seriously affects the efficiency of ncAA incorporation, always exists in codon reassignment. Competitors are classified into two categories: peptide release factors and endogenous aminoacyl-tRNA, and methods for eliminating competition include genome engineering, protein elimination, tRNA manipulation and amino acid replacement (Figure 2). Here, we discuss the challenges and opportunities of these current and emerging methods.
**Figure 2:** Different strategies for eliminating competition to ncAAs. (A) Genome engineering for deleting the prfA gene (corresponding to release factor 1 (RF1)), combined with amber codon replacement in essential genes (eGene). (B) Protein elimination strategies for the removal of RF1, including affinity tags, deactivating additives and protease degradation. (C) tRNA manipulation to erase specific tRNAs for ncAA reassignment, such as antisense DNA additives, DNA-hybridization chromatography and tRNA pool replacement. (D) Amino acid replacement with a customized amino acid pool containing ncAAs.

**Genome Engineering**

The amber codon (UAG), which is normally a translation termination signal recognized by peptide release factor 1 (RF1), is most commonly reassigned for ncAA incorporation. Deletion of the prfA gene encoding RF1 is a frequent strategy to improve the ncAA incorporation efficiency *in vivo* and *in vitro* [36]. Cell extracts from such strains have shown numerous advantages [37]. However, RF1 is essential for translation termination of over 300 genes in the genome, and the direct deletion of prfA
could seriously affect cell growth before cell extract preparation, even leading to cell death [22]. To address this problem, several detailed methods have been developed. These efforts and CFPS applications will be discussed in this section (Figure 2A).

The most direct method is the replacement of all amber codons with other stop codons, producing cells that do not need RF1, so that prfA can be knocked out without affecting cell viability. C321.ΔA is such an *E. coli* strain, whereby all of its 321 amber codons were replaced with ochre codons (UAA) [38]. Without RF1 competition, ncAAs can be incorporated into proteins at high efficiency. For instance, phosphoserine was efficiently incorporated into human MEK1 kinase using CFPS based on a cell extract of C321.ΔA, in which robust production reached up to milligram quantities [39]. By contrast, under RF1 competition in intracellular expression, only 25 μg of MEK1 containing phosphoserine was isolated from 1 liter of culture [12]. Recently, glycosylation enzymes were also successfully synthesized using this CFPS platform [14]. Furthermore, to improve the CFPS protein production capacity, great efforts were made to further improve C321.ΔA. Combined knockout of the genes endA, gor, rne, and mazF was shown to increase the yield of a model protein about five-fold, with up to 40 ncAAs [32]. Subsequently, a C321.ΔA variant that can express T7 RNA polymerase from the chromosome was created and optimized. CFPS based on a cell extract of this strain yielded up to 70 μg/mL of a model protein with 40 ncAAs, demonstrating a highly productive one-pot CFPS system [40].

In addition to full replacement of amber codons, partial replacement has also been demonstrated, in which only the stop codons of some essential genes were replaced. The strains RFzero, B95.ΔA and rEc.E13.ΔA are representatives of this strategy. The RFzero strain did not contain any replaced stop codons in chromosome. Ingeniously, it was introduced the BCA7 plasmid harboring seven essential genes (*coaD, hda, hemA, mreC, murF, lolA and lpxK*) with replaced stop codons for compensation. Subsequently, a chromosomal prfA deletion was carried out successfully, with only a minimal decrease of the cell growth rate [41-43]. Then, CFPS using a cell extract of the
RFzero strain was verified to incorporate six ncAAs with high efficiency and productivity [44]. The strains B60.ΔA and B95.ΔA were developed from *E.coli* strain BL21(DE3) by Yokoyama et al. by respectively replacing 60 and 90 chromosomal amber codons before *prfA* deletion [45]. Due to the rapid growth rates of B60.ΔA and B95.ΔA, a CFPS protocol for highly efficient incorporations of ncAAs was also described in detailed [46]. Before research on CFPS based on C321.ΔA, Jewett et al. developed the RF1 deletion strain rEc.E13.ΔA, which is homologous to C321.ΔA [47,48]. In conclusion, by bypassing the time, labor and cost needed for full codon replacement, a partial amber codon replacement strategy is a rapid and simple method for constructing the desired strains, even if the growth rate may be decreased to a certain extent. This method has been applied to diverse *E. coli* strains for various purposes, including MG1655, HST108, and BL21(DE3).

In addition to the established strains for CFPS, some genome engineering strains also have considerable potential to incorporate ncAAs in CFPS. Wang et al. found that *prfA* could be deleted unconditionally in *E. coli* B strain derivatives. Moreover, after reverting the RF2 A246T mutation back to Ala, *prfA* could also be knocked out in *E. coli* K12 strain derivatives, demonstrating that RF1 is nonessential in *E. coli* [36,49,50]. Without any stop codon replacement, it is the most rapid and simple method for RF1-free strain construction.

Although genome engineering provides a completely RF1 elimination strategy without residuals, these above methods also inevitably affect the activity and yield of CFPS and consume time and laborious for genetic manipulation. Consequently, additional strategies were developed for CFPS with unique advantages, which may be combined with genome engineering for future improvement.

**Protein Elimination**

Because the open reaction environment can be controlled directly, the CFPS system is more flexible than *in vivo* translation systems. Various competition eliminating strategies...
are only possible in the CFPS system with its special properties. An important strategy is protein elimination from the CFPS system. By manipulating protein levels, essential proteins can remain active to aid cell growth, but can be removed from the CFPS system to remove competition. For example, RF1 can be selectively removed using affinity tags, deactivating additives, or protease degradation (Figure 2B).

Selective removal of RF1 using an affinity tag has already been demonstrated by Otting et al.. This approach requires the genetic fusion of a chitin-binding domain sequence to prfA, so that the wild-type RF1 is replaced by a variant with three continuous chitin-binding domains at the C-terminus, which maintained the peptide release activity required for cell growth. After cell extract preparation, the lysate was filtered through a chitin column to selectively remove the tagged RF1, resulting in an improved CFPS system with efficient ncAA incorporation at multiple sites [51-53].

Similarly, the RF1 protein can also be eliminated by modifying the protein to make it sensitive to certain factors and eliminating it from the CFPS system. For example, a temperature-sensitive variant of RF1 had been engineered in E. coli, and the cell extract with a thermostensitive RF1 demonstrated a 11-fold increase of efficiency in ncAA incorporation following heat treatment [54]. However, longstanding heat shock may result in the loss of basic activity of the CFPS system, while too little heat can leave residual RF1. Recently, another strategy was developed with no need for heat shock. Hallam et al. successfully inserted an outer membrane protease (OmpT) recognition site into the switch loop of RF1. OmpT protease only identifies extracellular target proteins. Thus, the engineered RF1 can maintain the cell growth rate before cell extract preparation, after which it is cleaved by OmpT during cell lysis, which led to an increase of ncAA incorporation in CFPS [55].

These protein elimination strategies rely on the modification of proteins by genetic engineering. However, certain additives can also deactivate RF1 in the CFPS system. Sprinzl et al. used an anti-RF1 antibody to block RF1 activity in CFPS and improve
the ncAA incorporation efficiency [56]. Nonetheless, the antibody requires expression and purification steps, which increased the costs. Consequently, the easily prepared and adaptable RNA aptamers have also been investigated for RF1 inactivation [57,58]. For instance, an RNA aptamer that can orthogonally deactivate RF1 in CFPS was selected from a 50nt random sequence RNA pool, showing the ability to increase the efficiency of ncAA incorporation [59,60].

RF1 could be removed at either genome or protein level. By comparison, deletion of RF1 gene from genome completely get rid of RF1 bioactivity from cell. And RF1-deficient E. coli cells have demonstrated its potential in preparation of RF1-free cell extraction for incorporation of ncAA into protein. However, knockout of gene for RF1 generated side effects, such as slow cell growth. For instance, C321.ΔA has been evolved to improve cell viability by correcting mistakes of genetic manipulation, such as off-target modifications [61]. In contrast, RF1 elimination at protein level requires complicated procedures, such as chromatography, degradation or deactivation [51,55,56,60]. On the other hand, without stop codon replacements by multiple-sites genome editing, protein elimination strategy can be easily applied to other strains. However, due to the open nature of CFPS, more strategies can be flexibly designed.

**Manipulation of tRNAs**

When a ncAA is inserted into a protein at a sense codon, the endogenous aminoacyl-tRNA will compete with the ncAA aminoacyl-tRNA in the ribosome during translation, resulting in partially native protein. Directly manipulating tRNAs in the cell is unrealistic, but it is convenient in CFPS without a membrane barrier, freeing a large number of sense codons for ncAA incorporation by tRNA manipulation [62]. Considering the one-to-one correspondence between tRNAs and codons, artificial codon tables, and even minimum codon combinations can be achieved by tRNA manipulation in CFPS [63,64]. Recently, several tRNA level methods were developed, including tRNA
pool replacement, elimination using antisense oligonucleotides, and tRNA-specific enzymatic degradation (Figure 2C).

The most direct method is the replacement of all tRNAs with a tRNA pool customized according to research purposes. Due to the molecular weight of ~25,000 with 70-90 nucleotides in tRNAs, straightforward dialysis is not capable of removing tRNA from cell extracts and some small molecular translation enzymes, such as initiation factor 1, can be lost during dialysis [65]. Nevertheless, several methods for the replacement of endogenous tRNAs have been developed. Recently, a near-complete endogenous tRNA eliminating method was reported Bundy et al., in which RNase A was attached to magnetic beads to remove native tRNAs from cell extract [66]. Additionally, semisynthetic tRNA complements, which contain the majority of 48 synthetic tRNAs, were shown to be functional in CFPS, extending the ability to customize additive tRNA pools for ncAA incorporation at multiple sense codons [67].

Considering the time-consuming steps required for native tRNA removal and custom tRNA synthesis in the tRNA pool replacement strategy, tRNA antisense oligonucleotides have emerged as a powerful tool for tRNA-specific elimination and inactivation in CFPS. Alexandrov et al. removed the tRNA^Arg\textsubscript{CCU} by DNA-hybridization chromatography of tRNA-specific antisense oligonucleotides, displaying a universal method for sense codon reassignment [68]. However, without additional chromatography steps, methylated anti-tRNA oligonucleotides were demonstrated to deactivate multiple selected tRNAs by tRNA-DNA hybridization, which was induced due to heating and annealing with the tRNA mix of CFPS. This approach is more efficient than chromatography for tRNA inactivation [38].

In addition to tRNA-specific antisense oligonucleotides, the tRNA^Arg-specific tRNase, colicin D, was also utilized for specific tRNA elimination. Colicin D specifically cleaves tRNA^Arg at the anticodon loop, including tRNA^Arg\textsubscript{ACG}, tRNA^Arg\textsubscript{GCG}, tRNA^Arg\textsubscript{CCG}, tRNA^Arg\textsubscript{UCG}, tRNA^Arg\textsubscript{UCU}, and tRNA^Arg\textsubscript{CCU}, which can free six codons for reassignment [69]. Kang et al. utilized resin-bound colicin D to cleave all tRNA^Arg in the cell-free system and
supplemented synthetic tRNA$_{\text{Arg}}^{\text{CCU}}$ for arginine translation at a single codon, successfully demonstrating the recoding of four sense codons to ncAAs [70].

These tRNA manipulation strategies are able to free a large number of sense codons for efficient ncAA incorporation which are unattainable via stop codon suppression. Nonetheless, limitations still exist. For tRNA pool replacement, only 48 synthetic tRNAs were shown functional in CFPS, and the complete synthetic tRNA substitution pool was not achieved, which may hamper some specific artificial codon tables [67]. For specific tRNA elimination, the tRNAArg-specific tRNase (colicin D) method was limited by tRNase deficiency and could not be adopted more widely, while the tRNA antisense oligonucleotides may be a potential powerful tool for researchers.

Amino Acid Replacement

Due to the relaxed amino acid specificity of aaRS, a few ncAAs that are structurally similar to canonical amino acids can be charged to native tRNAs by corresponding aaRS. Examples include selenomethionine [71], fluorinated tryptophan analogs [72], chlorinated tyrosine analogs [73], 4-18F-fluoro-L-proline and 3,4-dihydroxy-L-phenylalanine [74]. Thus, structurally similar ncAAs can be incorporated in place of the corresponding native amino acids. In vivo, a few nutrient deficient strains lacking the specific amino acid biosynthesis enzymes have been constructed and cultured with supplementation of ncAAs for artificial protein expression [75,76]. However, ncAAs are toxic to the host strain because they will also be incorporated into essential endogenous proteins, resulting in a low growth rate and low protein yield. Moreover, residues of the corresponding canonical amino acid added during the preculture will also compete with the ncAA, leading to partially native protein.

Recently, CFPS was suggested to overcome these defects in amino acid analog incorporation. Even a detailed video protocol has been posted online [77]. A cell extract of a nutrient deficient strain lacking the specific amino acid biosynthesis enzymes was
prepared, followed by multiple diafiltration processes to remove all amino acids. The specific ncAA and 19 other canonical amino acids were added to the CFPS reaction for uncompetitive ncAA incorporation [73] (Figure 2D). For instance, L-DOPA, a tyrosine substitute, was incorporated into protein with almost eight times higher efficiency than competitive systems [30]. The highly toxic arginine analog canavanine was also firstly incorporated into proteins in a tyrosine-replaced CFPS system [78].

This amino acid replacement CFPS method has been a cost-effective and simple alternative to ncAA incorporation methodologies without requiring engineered aaRS or tRNAs. However, owing to the loss of replaced canonical amino acids, various potential applications, which need the 20 canonical amino acids, are limited in this method. What’s more, although the specific amino acid biosynthesis enzymes had been knock out in cell-free strains, which avoided other amino acids generating the omitted amino acid to make incorrect incorporations. The omitted amino acid may still be generated from metabolic process in cell extract, such as degradation of endogenous proteins. This problem may be solved by some protease-deficient strains in future studies.

**Incorporation of Multiple different ncAAs**

In addition to the incorporation of single ncAAs, the incorporation of multiple different ncAAs into the same protein has been achieved in vivo and in vitro, widely expanding the ability to engineer artificial proteins. By repeating ncAA reassigned codons in template, it is accessible to incorporate a single type ncAA into multiple different locations without methodological modification [32,36]. On the contrary, efficiently incorporating multiple different ncAAs into a single protein requires method improvements and modifications. So this section will focus on the emerging methods of multiple different ncAAs incorporation into a single protein. However, in vivo methods mainly relied on stop codon repression of the cell protein expression machine, leading to an undistinguished product yield due to the competition of peptide release factors
[79-82]. Only one release factor has been deleted, because the other peptide release factor must be retained for translational termination in cells. Consequently, the RF1-deficient strains, such as C321.ΔA, are currently the most appropriate host strain for reducing competition during the incorporation of multiple ncAAs [83]. Although up to three different ncAAs have been incorporated into the same protein in the C321.ΔA strain, the competition between ncAAs and peptide release factor 2 (RF2) still had negative effects in cells [23].

Recently, cell extracts of RF1-deficient strains were also utilized in a CFPS system for efficient and modular artificial protein expression with multiple different ncAAs, but partial competition was still present, similar to the cells [48,84,85]. Further, several total competition-removing CFPS methods were developed using different strategies. For instance, Alexandrov et al. combined tRNA-specific affinity chromatography with stop codon repression in RF1-deficient strains for dual protein fluorescent labeling by incorporating AzF and BPFL-Cys into a single protein [68]. This opens up the possibility of combining approaches at different levels to engineer proteins more freely.

**Translation Factors Engineering**

Various factors play important role in protein translation as well, especially in ncAA incorporation. These translation factors are also engineered to facilitate efficient ncAA incorporation. In this part, engineering achievement of elongation factor Tu (EF-Tu), ribosome and aaRS/tRNA pairs are summarized and discussed.

**EF-Tu**

EF-Tu is crucial in translation elongation phase, which is abundant in E. coli [86]. EF-Tu binds aminoacyl-tRNA and delivery them to the ribosome for peptide elongation. However, EF-Tu may not efficiently bind to ncAA with macromolecular or negatively charged groups, leading to ineffective incorporation [25,87]. Thus far, many efforts had been made to improve EF-Tu in ncAA incorporation by engineering the amino acid binding domain.
With evolution of the binding domain in EF-Tu, ncAAs such as phosphoserine, phosphotyrosine, selenocysteine, pyrenylalanine and p-azido-phenylalanine, were efficiently incorporated into peptide. Some ncAAs carrying negative charged phosphorylation side chain are hard to be recognized by wild type EF-Tu. Therefore, mutant EF-Tu (H67R, E216N, D217G, F219Y, T229S, N274W) was developed to efficiently incorporated phosphoserine into peptide [12] and milligram of protein with phosphoserine incorporation was obtained in cell-free system extracted from strain C321.ΔA [39]. Similarly, the EF-Tu variant (E216V, D217G, F219G) was also successfully selected for phosphotyrosine incorporation [88]. And selenocysteine, another negatively charged amino acid, was also efficiently recognized by EF-Tu variant (H67Y, Q98Q, E216D, D217R, N274R) [25]. Doi et al. developed EF-Tu mutants (E215A and D216A), in which the binding pocket of aminoacyl-tRNA was enlarged, to improve the binding of ncAAs carrying bulky side chain and this system successfully worked with ncAAs of L-1-pyrenylalanine, L-2-pyrenylalanine, and DL-2-anthraquinonylalanine as well [88]. Incorporation of p-azido-phenylalanine was assisted by EF-Tu with mutant binding domain (S65A, D216A, and V274A) [89]. Although the function of these EF-Tu variants has been proved in vivo, it is easy to applied them in CFPS by either direct addition of purified EF-Tu variants protein or co-expression with other endogenous wild-type translation factors in cell. For instance, protein with phosphoserine incorporation was synthesized to milligram in CFPS with engineered EF-Tu [39].

**Ribosome**

Besides the normal proteinogenic amino acids, wild-type ribosome is also able to accept some analogues of L-α-amino acids [90]. Nonetheless, ncAAs with modified chemical backbone such as partial D-amino acids were incompatible with the wild-type translation machinery [91]. Modification of the peptidyl transferase center on ribosomal 50S subunit has high potential to enhance special ncAAs incorporation. For instance, the mutant 23s rRNA mutations (region of 2447-2451, 2457-2462, 2057-2063 and 2502-2507) allowed efficient peptidyl
transfer of D-amino acids or β-amino acids, such as D-methionine, D-phenylalanine [92,93], β-alanine and β-phenylalanine [94,95]. Interestingly, mutant 16S rRNA (A238U, G849U, G1175U, G1516U) was identified as well with improved activity for selenocysteine incorporation [96]. Moreover, several novel features have been evolved in ribosome to improve ncAA incorporation. Wang et al. developed an orthogonal ribosome with a decreased functional interaction with RF1 and improved amber codon suppression [97]. Another orthogonal ribosome was developed for efficient quadruplet codon suppression [98]. Engineered ribosome may bring the risk of losing cell viability especially under overexpression [92,93]. Therefore, specially designed orthogonal ribosome may be the good solution, by which ncAA incorporation could be separated from endogenous translation and minimize the influence on cell viability.

**Evolution of aaRS/tRNA Pairs**

Aminoacylation is the key procedure for orthogonality of tRNA and corresponding amino acids. Thus far, a few of specific aaRS/tRNA pairs were developed, such as the PylRS/tRNA pair for lysine, phenylalanine and pyrrolysine analogues from Methanosarcina spp. [99-101], Methanococcus jannaschii and acetivorans TyrRS/tRNA pairs for tyrosine analogues [102], Methanococcus maripaludis SepRS/tRNA pair for phosphoserine [13], Saccharomyces cerevisiae PheRS/tRNA pair for phenylalanine and alanine analogues [103], Saccharomyces cerevisiae TrpRS/tRNA pair for tryptophan and alanine analogues [104], Desulfitobacterium hafniense PylRS/tRNA for lysine analogues and Pyrocococcus horikoshii ProRS/tRNA for proline analogues [105].

However, the slow incorporation rate of nnAAs charged aminoacyl-tRNA leads to increased misincorporation of the endogenous aminoacyl-tRNA, inserting undesired canonical amino acid [106]. Additionally, the site-specific incorporation requires accurate aminoacylation reaction between ncAA and its partner tRNA. Thus, directed evolution was applied to evolve efficient and accurate aaRS/tRNA pairs, including phage-
assisted continuous evolution (PACE) [107], compartmentalized partnered replication (CPR) [108], parallel positive selection combined with deep sequencing and tRNA Extension (tREX) assisted with computationally identification [109,110]. And improved efficiency and specificity have been demonstrated for aaRS/tRNA pairs of Nε-Boc-L-lysine (BocK), Nε-acetyl-L-lysine (AcK) [111], p-azido-L-phenylalanine (pAzF) [112], 3-iodo-L-tyrosine [113]. O-methyl-L-tyrosine [110], and so on. However, the degree of the orthogonality of these evolved aaRS/tRNA pairs is crucial for in vivo application. All of these evolved aaRS/tRNA pairs could also be applied in CFPS by either directly addition of purified protein or pre-expression in the cell. And, the activity of orthogonal aaRS/tRNA could be improved by accurately adjusting its relative concentration in cell-free system.

Novel ncAAs and in vitro Aminoacylation Methods for CFPS

Without limitations of cell viability and membrane barrier, CFPS allows the direct addition of specific aminoacyl-tRNA to participate in ribosomal translation, in which the aminoacyl-tRNA is pre-synthesized before the CFPS reaction. By decoupling aminoacylation and translation in CFPS, several limitations can be overcome. On the one hand, because the ncAA aminoacylation reaction is physically separated from endogenous reactions, the orthogonality of aaRS is unnecessary, so that time-consuming enzyme evolution can be avoided and more ncAAs can be utilized by in vitro aminoacylation [114]. On the other hand, more chemical and enzymatic methods can be utilized to generate aminoacyl-tRNAs, breaking the limitation that only analogues of L-α-amino acids can be charged by aaRS [115,116]. Through in vitro aminoacylation methods, orthogonality requirement of aminoacylation process can be avoided, in which tRNA can only be charged by the only amino acid in vitro. But after translation, the released tRNA may be recharged by endogenous aaRS if it is not orthogonal to endogenous system, possibly resulting in incorrect incorporation. Thus, orthogonality evolution of aminoacylation factors can be skipped to save cost, while orthogonal tRNA is needed to
achieve accurate ncAAs incorporation. Recently, several novel ncAAs were successfully incorporated into protein by such *in vitro* aminoacylation methods, including D-α-amino acids [34], β-amino acids [35], γ-amino acids [117], N-alkylated-α-amino acids [118], N-acylated-α-amino acids [119], α-hydroxy acids [33], α-benzoic acids and even foldamers [120,121] (Figure 3).

**Figure 3**: Recently developed novel ncAAs only utilized in CFPS. (A) L-α-amino acids with non-canonical side chains, which can only be charged to tRNAs *in vitro*. (B) D-α-amino acids. (C) N-alkylated-α-amino acids. (D) N-acylated-α-amino acids. (E) α-hydroxy acids. (F) α-benzoic acid. (G) β-amino acids. (H) γ-amino acids. (I) quinoline-based foldamers. (J) pyridine-based foldamer.

These novel ncAAs widely expand the ability to engineer artificial proteins with novel features, which may increase the proteolytic stability, membrane permeability, and conformational rigidity of the peptide. For instance, the thioether macrocyclic peptides incorporated with D-amino acids could provide high serum stability due to structural difference and protease resistance [122]. And β-amino acids were considered as the potential building blocks of peptide analogues for pharmaceutical uses with the improved stability against proteolysis [94]. Cyclic peptide antagonists containing N-alkylated-α-amino acids also showed more membrane-permeable and stable to proteolysis [123,124]. The foldamers may potentially be highly water-soluble and possess cell-penetrating
properties [125]. However, more applications are limited by preparation method of peptide with novel ncAAs. In this part, novel amino acids and different in vitro aminoacylation methods for CFPS platforms will be summarized and discussed.

**In vitro Aminoacylation by aaRS**

Utilizing the relaxed amino acid specificity of some aaRS, a few analogues of L-α-amino acids can be directly charged to tRNAs by aaRS [126] (Figure 4A). When aminoacylation and translation are conducted in the same system, in order to avoid competition between amino acids in the same aaRS/tRNA pair, the corresponding canonical amino acid should be removed to safeguard the orthogonality of the translation machine. Via pre-aminoacylation with ncAAs by aaRS, not only any codon, including stop codons, can be reassigned to a ncAA with a defined aminoacyl-tRNA, but also more efficient ncAA incorporation can be realized by optimizing additive concentrations [127]. For instance, the general method for the expression of isotopically labeled proteins relies on aaRS charging isotopically labeled amino acids. With $[^{15}\text{N},^{13}\text{C}]-\text{glutamine}$ pre-charged by yeast glutaminyl-tRNA synthetase, homogeneous protein was obtained for high-dimensional NMR spectroscopy [118].

Another method is the chemical modification of side chains in canonical aminoacyl-tRNAs after normal aminoacylation by aaRS, generating ncAA aminoacyl-tRNAs to participate in translation (Figure 4A). Several side chains were successfully modified in canonical aminoacyl-tRNAs, generating moieties such as phenyllactyl amino acids [128], N-methyl amino acids [129], glycosyl amino acids [130], fluorescence labeled amino acids and BODIPY labeled amino acids [131].
Figure 4: In vitro aminoacylation methods combined with CFPS. (A) In vitro aminoacylation by aaRS. Without an orthogonality barrier, extracellular aaRS can load tRNAs with more kinds of ncAAs. Canonical amino acid (cAA) aminoacyl-tRNAs can be chemically modified to become non-canonical. (B) Chemical aminoacylation. The truncated tRNA can be ligated with chemically aminoacylated pCpA-ncAA by T4 RNA ligase, generating a complete ncAA aminoacyl-tRNA. (C) Ribozyme aminoacylation. Flexizymes can synthesize aminoacyl-tRNAs from ncAAs with different activated carboxyl groups.

Compared to in vivo methods relying on introducing orthogonal aaRS/tRNA pairs into cells, in vitro aminoacylation by aaRS physically separates the ncAA aminoacylation reaction from endogenous reactions, avoiding orthogonality requirement of aaRS in ncAA aminoacylation process. The cost and time-consuming aaRS evolution can be skipped. And available ncAAs are expanded without orthogonality. However, after the dehydration condensation reaction in ribosome, the released tRNA could be recharged with unwished amino acids if it is not orthogonal to endogenous aaRS, leading to misincorporations. For precise and efficient ncAA incorporation, the corresponding tRNA needs to be orthogonal to endogenous systems. What’s
more, the available specter of ncAAs is still largely limited to analogues of L-α-amino acids.

**Chemical Aminoacylation**

Chemical aminoacylation is a versatile classical strategy for aminoacyl-tRNA synthesis *in vitro* [132] (Figure 4B). Although several improvements have been made, the general process remained consistent [116,119,133-135]. The amino acid with appropriate protecting groups is chemically charged to the 3’-OH of pCpA or pdCpA, which was chemical synthesized. Subsequently, the corresponding truncated tRNA, lacking two bases at the 3’-terminal, is ligated with aminoacyl-pCpA (or pdCpA) by T4 RNA ligase to generate the complete aminoacyl-tRNA. In theory, this method can be used to load any tRNA with any desired amino acid, such as N-acetyl amino acids [136], glycosylated serine and tyrosine [130], N-methyl and N-nitro arginine [137], citrulline [138], homoarginine and isotopically labeled canonical amino acids [139].

In theory, the greatest strength of this method is that any desired amino acid can be charged to any tRNA. However, the combination of chemical synthesis with enzymatic ligation is labor-intensive and it is challenging to produce homogeneous aminoacyl-tRNAs. Especially the primary by-product, self-ligated tRNA, is unavoidably generated by T4 RNA ligase, leading to inefficient synthesis, which may be avoided in future researches.

**Ribozyme Aminoacylation**

In addition to aaRS and chemical aminoacylation, Suga et al. evolved small ribozymes (44-46nt) that synthesize aminoacyl-tRNAs. These so-called flexizymes can charge tRNAs with amino acids with an activated carboxyl group [115,140]. This activated carboxyl group and the 3’-terminal NCCA sequence of tRNA are crucial recognized sites of the flexizyme catalytic domain [141]. Therefore, in theory, the ncAA can be reassigned to any codon. Recently, some flexizyme variants were artificially evolved to accept amino acids with different activated carboxyl
groups [142]. The aFx, dFx and eFx flexizymes are three widely used representatives, respectively recognizing amino acids carrying an activated amino-derivatized benzyl thioester (ABT), dinitrobenzyl ester (DBE) or chlorobenzyl ester (CBE) [143,144] (Figure 4C). More recently, more than thirty activated groups were verified to be accessible to flexizyme aminoacylation, significantly expanding the range of available amino acids [145].

As an emerging method, flexizyme aminoacylation has been applied as a versatile strategy for the incorporation of a great many ncAAs. The only two limitations imposed on the amino acids are the feasibility to activate the carboxyl with a certain group and chemical stability during the aminoacylation process. In fact, different ncAAs have been utilized even with multiple incorporations, including D-α-amino acids [34], β-amino acids [35], γ-amino acids [117], α-hydroxy acids [33], α-benzoic acids [120], N-alkyl-L-α-amino acids [118], N-methyl-L-α-amino acids [119], and even foldamers [121]. However, the efficiency of flexizyme aminoacylation varies depending on the ncAAs with a wide range of 17-91%, which can only be optimized empirically, since there are no established design rules [140]. Moreover, the ribosome incorporation capacity of ncAA aminoacyl-tRNAs also ranges from zero to high efficiency. For instance, only eight of nineteen D-α-amino acids showed highly efficient incorporation, while low efficiencies were observed in four D-α-amino acids and the other was incompatible with the ribosome [146,147]. Henceforth, more versatile aminoacylation and translation techniques are worth developing to satisfy the increasing demand for ncAA incorporation.

**Conclusions and Prospects**

CFPS has emerged as a powerful platform for engineering the genetic code with its unique advantages allowing the efficient and extensive incorporation of ncAAs, which were summarized in this review. To improve the efficiency and yield of artificial proteins, several strategies have been presented to remove ncAA competitors at different levels, including genome engineering, elimination of peptide release factors, tRNA manipulation and amino acid replacement. The pros and cons of these strategies
have been discussed in detail above. By combining methods at
different levels, multiple codons, including sense and nonsense
codons, could be simultaneously reassigned to different ncAAs
without endogenous competitors, contributing to more flexible
artificial protein synthesis [68]. To enhance ncAA incorporation,
several translation factors have been engineered for
improvement, such as EF-Tu, ribosome and aaRS/tRNA pairs.
At the same time, CFPS is compatible with in vitro
aminoacylation methods, which can supply a wider range of
novel and unique ncAAs for artificial protein research.
Compared with aaRS and chemical aminoacylation methods,
flexizymes have been developed into a highly versatile and
efficient approach for aminoacyl-tRNA synthesis, with many
recent studies confirming its expansion. By emphasizing these
crucial techniques for ncAA incorporation via CFPS, this review
is intended to provide a bridge between current technologies and
future directions in this rapidly developing field.

Looking forward, these tools have the potential to be applied in
various emerging fields, such as antibody-drug conjugates,
protein labeling, peptide-based materials and so on [17,29,148].
Especially in enzyme activity improvement, several efforts have
been made with significant influence. For instance, enzyme
phosphorylation is a key modification for protein activity, which
may occur on tyrosines, threonines and serines. Phosphotyrosine
and phosphothreonine were used to activate vasodilator-
stimulated phosphoprotein (VASP) and the nicotinic acetyl
choline receptor (nAChR) [149]. With phosphoserine
incorporation, several homogeneous phosphorylated enzymes
have been expressed, such as human MEK1 kinase, human
Stimulator of Interferon Genes (STING) and Bcl2-associated
agonist of cell death (BAD) [39,150]. Furthermore,
methylhistidine also showed important activating effects in the
enzyme catalytic center of fluorescent proteins, heme enzymes,
and metalloenzymes [151-153]. Acetyllysine and methyllysine
play a crucial role in the control of chromatin and epigenetic
programs by histones, which has been demonstrated by site-
specific incorporation with in vitro aminoacylation in CFPS
[154-157]. In addition, numerous unclear modifications of amino
acids in the enzymatic active center need to be investigated in
the future, such as hydroxylation, glycosylation, sulfation and amidation. Overall, this review hopes to assist researchers in choosing suitable methods to incorporate ncAAs efficiently and easily using CFPS, hopefully inspiring breakthroughs of ncAA techniques and applications in the future.

References

1. Liu WQ, Zhang L, Chen M, Li J. Cell-free protein synthesis: Recent advances in bacterial extract sources and expanded applications. Biochemical Engineering Journal. 2019; 141: 182-189.
2. Silverman AD, Karim AS, Jewett MC. Cell-free gene expression: an expanded repertoire of applications. Nat Rev Genet. 2019; 21: 151-170.
3. Lu Y. Cell-free synthetic biology: Engineering in an open world. Synth Syst Biotechnol. 2017; 2: 23-27.
4. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, et al. Cell-free translation reconstituted with purified components. Nat Biotechnol. 2001; 19: 751-755.
5. Wang HH, Huang PY, Xu G, Haas W, Marblestone A, et al. Multiplexed in vivo His-tagging of enzyme pathways for in vitro single-pot multienzyme catalysis. ACS Synth Biol. 2012; 1: 43-52.
6. Shepherd TR, Du L, Liljeruhm J, Samudyata, Wang J, et al. De novo design and synthesis of a 30-cistron translation-factor module. Nucleic Acids Research. 2017; 45: 10895-10905.
7. Villarreal F, Contreras-Llano LE, Chavez M, Ding Y, Fan J, et al. Synthetic microbial consortia enable rapid assembly of pure translation machinery. Nat Chem Biol. 2018; 14: 29-35.
8. Lavickova B, Maerkl SJ. A Simple, Robust, and Low-Cost Method To Produce the PURE Cell-Free System. ACS Synth Biol. 2019; 8: 455-462
9. Dopp BJL, Tamiev DD, Reuel NF. Cell-free supplement mixtures: Elucidating the history and biochemical utility of additives used to support in vitro protein synthesis in E. coli extract. Biotechnol Adv. 2019; 37: 246-258.
10. Karim AS, Jewett MC. A cell-free framework for rapid biosynthetic pathway prototyping and enzyme discovery.
11. Narumi R, Masuda K, Tomonaga T, Adachi J, Ueda HR, et al. Cell-free synthesis of stable isotope-labeled internal standards for targeted quantitative proteomics. Synth Syst Biotechnol. 2018; 3: 97-104.

12. Park HS, Hohn MJ, Umehara T, Guo LT, Osborne EM, et al. Expanding the genetic code of Escherichia coli with phosphoserine. Science. 2011; 333: 1151-1154.

13. Rogerson DT, Sachdeva A, Wang K, Haq T, Kazlauskaite A, et al. Efficient genetic encoding of phosphoserine and its nonhydrolyzable analog. Nat Chem Biol. 2015; 11: 496-503.

14. Kightlinger W, Duncker KE, Ramesh A, Thames AH, Natarajan A, et al. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways. Nat Commun. 2019; 10: 5404.

15. Si LL, Xu H, Zhou XY, Zhang ZW, Tian ZY, et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science. 2016; 354: 1170-1173.

16. Bundy BC, Franciszkowicz MJ, Swartz JR. Escherichia coli-based cell-free synthesis of virus-like particles. Biotechnol Bioeng. 2008; 100: 28-37.

17. Albayrak C, Swartz JR. Direct polymerization of proteins. ACS Synth Biol. 2014; 3: 353-362.

18. Ravikumar Y, Nadarajan SP, Yoo TH, Lee CS, Yun H. Unnatural amino acid mutagenesis-based enzyme engineering. Trends Biotechnol. 2015; 33: 462-470.

19. Gfeller D, Michielin O, Zoete V. SwissSidechain: a molecular and structural database of non-natural sidechains. Nucleic Acids Res. 2013; 41: D327-332.

20. Dumas A, Lercher L, Spicer CD, Davis BG. Designing logical codon reassignment - Expanding the chemistry in biology. Chem Sci. 2015; 6: 50-69.

21. Hu C, Chan SI, Sawyer EB, Yu Y, Wang J. Metalloprotein design using genetic code expansion. Chem Soc Rev. 2014; 43: 6498-6510.

22. Chin JW. Expanding and reprogramming the genetic code. Nature. 2017; 550: 53-60.

23. Italia JS, Addy PS, Erickson SB, Peeler JC, Weerapana E, et al. Mutually Orthogonal Nonsense-Suppression Systems and Conjugation Chemistries for Precise Protein Labeling at up
to Three Distinct Sites. J Am Chem Soc. 2019; 141: 6204–6212.

24. Kawakami T, Murakami H, Suga H. Messenger RNA-programmed incorporation of multiple N-methyl-amino acids into linear and cyclic peptides. Chem Biol. 2008; 15: 32-42.

25. Haruna K, Alkazemi MH, Liu Y, Soll D, Englert M. Engineering the elongation factor Tu for efficient selenoprotein synthesis. Nucleic Acids Res. 2014; 42: 9976-9983.

26. Katoh T, Iwane Y, Suga H. Logical engineering of D-arm and T-stem of tRNA that enhances d-amino acid incorporation. Nucleic Acids Res. 2017; 45: 12601-12610.

27. Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem. 2014; 25: 351-361.

28. Schinn SM, Bradley W, Groesbeck A, Wu JC, Broadbent A, et al. Rapid in vitro screening for the location-dependent effects of unnatural amino acids on protein expression and activity. Biotechnol Bioeng. 2017; 114: 2412-2417.

29. Stech M, Nikolaeva O, Thoring L, Stocklein WFM, Wustenhagen DA, et al. Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates. Sci Rep. 2017; 7: 12030.

30. Lee KH, Catherine C, Kim DM. Enhanced production of unnatural amino acid-containing proteins in a cell-free protein synthesis system. Journal of Industrial and Engineering Chemistry. 2016; 37: 90-94.

31. Cui Z, Wu Y, Mureev S, Alexandrov K. Oligonucleotide-mediated tRNA sequestration enables one-pot sense codon reassignment in vitro. Nucleic Acids Res. 2018; 46: 6387-6400.

32. Martin RW, Des Soye BJ, Kwon YC, Kay J, Davis RG, et al. Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids. Nat Commun. 2018; 9: 1203.

33. Ohta A, Murakami H, Suga H. Polymerization of alpha-hydroxy acids by ribosomes. Chembiochem. 2008; 9: 2773-2778.
34. Katoh T, Tajima K, Suga H. Consecutive Elongation of D-Amino Acids in Translation. Cell Chem Biol. 2017; 24: 46-54.
35. Katoh T, Suga H. Ribosomal Incorporation of Consecutive beta-Amino Acids. J Am Chem Soc. 2018; 140: 12159-12167.
36. Johnson DB, Xu J, Shen Z, Takimoto JK, Schultz MD, et al. RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. Nat Chem Biol. 2011; 7: 779-786.
37. Smolskaya S, Logashina YA, Andreev YA. Escherichia coli Extract-Based Cell-Free Expression System as an Alternative for Difficult-to-Obtain Protein Biosynthesis. Int J Mol Sci. 2020; 21.
38. Lajoie MJ, Rovner AJ, Goodman DB, Aerni HR, Haimovich AD, et al. Genomically recoded organisms expand biological functions. Science. 2013; 342: 357-360.
39. Oza JP, Aerni HR, Pirman NL, Barber KW, Ter Haar CM, et al. Robust production of recombinant phosphoproteins using cell-free protein synthesis. Nat Commun. 2015; 6: 8168.
40. Des Soye BJ, Gerbasi VR, Thomas PM, Kelleher NL, Jewett MC. A Highly Productive, One-Pot Cell-Free Protein Synthesis Platform Based on Genomically Recoded Escherichia coli. Cell Chem Biol. 2019; 26: 1743-1754 e1749.
41. Mukai T, Hayashi A, Iraha F, Sato A, Ohtake K, et al. Codon reassignment in the Escherichia coli genetic code. Nucleic Acids Res. 2010; 38: 8188-8195.
42. Mukai T, Yanagisawa T, Ohtake K, Wakamori M, Adachi J, et al. Genetic-code evolution for protein synthesis with non-natural amino acids. Biochem Biophys Res Commun. 2011; 411: 757-761.
43. Ohtake K, Sato A, Mukai T, Hino N, Yokoyama S, et al. Efficient decoding of the UAG triplet as a full-fledged sense codon enhances the growth of a prfA-deficient strain of Escherichia coli. J Bacteriol. 2012; 194: 2606-2613.
44. Adachi J, Katsura K, Seki E, Takemoto C, Shirouzu M, et al. Cell-Free Protein Synthesis Using S30 Extracts from Escherichia coli RFzero Strains for Efficient Incorporation of Non-Natural Amino Acids into Proteins. Int J Mol Sci.
45. Mukai T, Hoshi H, Ohtake K, Takahashi M, Yamaguchi A, et al. Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon. Sci Rep. 2015; 5: 9699.

46. Seki E, Yanagisawa T, Yokoyama S. Cell-Free Protein Synthesis for Multiple Site-Specific Incorporation of Noncanonical Amino Acids Using Cell Extracts from RF-1 Deletion E. coli Strains. Methods Mol Biol. 2018; 1728: 49-65.

47. Hong SH, Kwon YC, Martin RW, Des Soye BJ, de Paz AM, et al. Improving cell-free protein synthesis through genome engineering of Escherichia coli lacking release factor 1. Chembiochem. 2015; 16: 844-853.

48. Hong SH, Ntai I, Haimovich AD, Kelleher NL, Isaacs FJ, et al. Cell-free protein synthesis from a release factor 1 deficient Escherichia coli activates efficient and multiple site-specific nonstandard amino acid incorporation. ACS Synth Biol. 2014; 3: 398-409.

49. Johnson DB, Wang C, Xu J, Schultz MD, Schmitz RJ, et al. Release factor one is nonessential in Escherichia coli. ACS Chem Biol. 2012; 7: 1337-1344.

50. Wang L. Engineering the Genetic Code in Cells and Animals: Biological Considerations and Impacts. Acc Chem Res. 2017; 50: 2767-2775.

51. Loscha KV, Herlt AJ, Qi R, Huber T, Ozawa K, et al. Multiple-site labeling of proteins with unnatural amino acids. Angew Chem Int Ed Engl. 2012; 51: 2243-2246.

52. Abdelkader EH, Feintuch A, Yao X, Adams LA, Aurelio L, et al. Protein conformation by EPR spectroscopy using gadolinium tags clicked to genetically encoded p-azido-L-phenylalanine. Chem Commun (Camb). 2015; 51: 15898-15901.

53. Jabar S, Adams LA, Wang Y, Aurelio L, Graham B, et al. Chemical Tagging with tert-Butyl and Trimethylsilyl Groups for Measuring Intermolecular Nuclear Overhauser Effects in a Large Protein-Ligand Complex. Chemistry. 2017; 23: 13033-13036.

54. Short GF, Golovine SY, Hecht SM. Effects of release factor 1 on in vitro protein translation and the elaboration of
proteins containing unnatural amino acids. Biochemistry. 1999; 38: 8808-8819.

55. Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, et al. RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates. Sci Rep. 2017; 7: 3026.

56. Agafonov DE, Huang Y, Grote M, Sprinzl M. Efficient suppression of the amber codon in E. coli in vitro translation system. FEBS Lett. 2005; 579: 2156-2160.

57. Szkaradkiewicz K, Nanninga M, Nesper-Brock M, Gerrits M, Erdmann VA, et al. RNA aptamers directed against release factor 1 from Thermus thermophilus. FEBS Letters. 2002; 514: 90-95.

58. Shafer AM, Kálai T, Liu SQB, Hideg K, Voss JC. Site-specific insertion of spin-labeled L-amino acids in Xenopus oocytes. Biochemistry. 2004; 43: 8470-8482.

59. Ogawa A, Nishi T, Sando S, Aoyama Y. In vitro selection of RNA aptamers for the Escherichia coli release factor 1. Nucleic Acids Symp Ser (Oxf). 2005; 49: 269-270.

60. Sando S, Ogawa A, Nishi T, Hayami M, Aoyama Y. In vitro selection of RNA aptamer against Escherichia coli release factor 1. Bioorg Med Chem Lett. 2007; 17: 1216-1220.

61. Wannier TM, Kunjapur AM, Rice DP, McDonald MJ, Desai MM, et al. Adaptive evolution of genomically recoded Escherichia coli. Proc Natl Acad Sci U S A. 2018; 115: 3090-3095.

62. Tajima K, Katoh T, Suga H. Genetic code expansion via integration of redundant amino acid assignment by finely tuning tRNA pools. Curr Opin Chem Biol. 2018; 46: 212-218.

63. Calles J, Justice I, Brinkley D, Garcia A, Endy D. Fail-safe genetic codes designed to intrinsically contain engineered organisms. Nucleic Acids Res. 2019; 47: 10439-10451.

64. Wang T, Liang C, An Y, Xiao S, Xu H, et al. Engineering the Translational Machinery for Biotechnology Applications. Mol Biotechnol. 2020; 62: 219-227.

65. Bhat SV, Nagasampagi BA, Sivakumar M. Chemistry of natural products. Berlin: Springer Science & Business Media. 2005.

66. Salehi ASM, Smith MT, Schinn SM, Hunt JM, Muhlestein
C, et al. Efficient tRNA degradation and quantification in Escherichia coli cell extract using RNase-coated magnetic beads: A key step toward codon emancipation. Biotechnol Prog. 2017; 33: 1401-1407.

67. Cui Z, Stein V, Tnimov Z, Mureev S, Alexandrov K. Semisynthetic tRNA complement mediates in vitro protein synthesis. J Am Chem Soc. 2015; 137: 4404-4413.

68. Cui Z, Mureev S, Polinkovsky ME, Tnimov Z, Guo Z, et al. Combining Sense and Nonsense Codon Reassignment for Site-Selective Protein Modification with Unnatural Amino Acids. ACS Synth Biol. 2017; 6: 535-544.

69. Tomita K, Ogawa T, Uozumi T, Watanabe K, Masaki H. A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops. Proc Natl Acad Sci U S A. 2000; 97: 8278-8283.

70. Lee KB, Hou CY, Kim CE, Kim DM, Suga H, et al. Genetic Code Expansion by Degeneracy Reprogramming of Arginyl Codons. Chembiochem. 2016; 17: 1198-1201.

71. Kigawa T, Yamaguchi-Nunokawa E, Kodama K, Matsuda T, Yabuki T, et al. Selenomethionine incorporation into a protein by cell-free synthesis. J Struct Funct Genomics 2002; 2: 29-35.

72. Mat WK, Xue H, Wong JT. Genetic code mutations: the breaking of a three billion year invariance. PLoS One. 2010; 5: e12206.

73. Singh-Blom A, Hughes RA, Ellington AD. An amino acid depleted cell-free protein synthesis system for the incorporation of non-canonical amino acid analogs into proteins. J Biotechnol. 2014; 178: 12-22.

74. Harada R, Furumoto S, Yoshikawa T, Ishikawa Y, Shibuya K, et al. Synthesis and Characterization of (1)(8)F-Interleukin-8 Using a Cell-Free Translation System and 4-(1)(8)F-Fluoro-L-Proline. J Nucl Med. 2016; 57: 634-639.

75. Budisa N, Pal PP, Alefelder S, Birle P, Krywcuin T, et al. Probing the role of tryptophans in Aequorea victoria green fluorescent proteins with an expanded genetic code. Biol Chem. 2004; 385: 191-202.

76. Montclare JK, Son S, Clark GA, Kumar K, Tirrell DA. Biosynthesis and stability of coiled-coil peptides containing (2S,4R)-5,5,5-trifluoroleucine and (2S,4S)-5,5,5-
trifluoroleucine. Chembiochem. 2009; 10: 84-86.
77. Worst EG, Exner MP, De Simone A, Schenkelberger M, Noireaux V, et al. Residue-specific Incorporation of Noncanonical Amino Acids into Model Proteins Using an Escherichia coli Cell-free Transcription-translation System. J Vis Exp. 2016; 114.
78. Worst EG, Exner MP, De Simone A, Schenkelberger M, Noireaux V, et al. Cell-free expression with the toxic amino acid canavanine. Bioorg Med Chem Lett. 2015; 25: 3658-3660.
79. Wan W, Huang Y, Wang Z, Russell WK, Pai PJ, et al. A facile system for genetic incorporation of two different noncanonical amino acids into one protein in Escherichia coli. Angew Chem Int Ed Engl. 2010; 49: 3211-3214.
80. Chatterjee A, Sun SB, Furman JL, Xiao H, Schultz PG. A versatile platform for single- and multiple-unnatural amino acid mutagenesis in Escherichia coli. Biochemistry. 2013; 52: 1828-1837.
81. Wang K, Sachdeva A, Cox DJ, Wilf NM, Lang K, et al. Optimized orthogonal translation of unnatural amino acids enables spontaneous protein double-labelling and FRET. Nat Chem. 2014; 6: 393-403.
82. Venkat S, Sturges J, Stahman A, Gregory C, Gan Q, et al. Genetically Incorporating Two Distinct Post-translational Modifications into One Protein Simultaneously. ACS Synth Biol. 2018; 7: 689-695.
83. Zheng Y, Gilgenast MJ, Hauc S, Chatterjee A. Capturing Post-Translational Modification-Triggered Protein-Protein Interactions Using Dual Noncanonical Amino Acid Mutagenesis. ACS Chem Biol. 2018; 13: 1137-1141.
84. Ozer E, Chemla Y, Schlesinger O, Aviram HY, Riven I, et al. In vitro suppression of two different stop codons. Biotechnol Bioeng. 2017; 114: 1065-1073.
85. Chemla Y, Ozer E, Shaferman M, Zaab D, Dandel R, et al. Simplified methodology for a modular and genetically expanded protein synthesis in cell-free systems. Synth Syst Biotechnol. 2019; 4: 189-196.
86. Furano AV. Content of elongation factor Tu in Escherichia coli. Proceedings of the National Academy of Sciences. 1975; 72: 4780-4784.
87. Doi Y, Ohtsuki T, Shimizu Y, Ueda T, Sisido M. Elongation factor Tu mutants expand amino acid tolerance of protein biosynthesis system. J Am Chem Soc. 2007; 129: 14458-14462.
88. Fan C, Ip K, Soll D. Expanding the genetic code of Escherichia coli with phosphotyrosine. FEBS Lett. 2016; 590: 3040-3047.
89. Gan R, Perez JG, Carlson ED, Ntai I, Isaacs FJ, et al. Translation system engineering in Escherichia coli enhances non-canonical amino acid incorporation into proteins. Biotechnol Bioeng. 2017; 114: 1074-1086.
90. Dedkova LM, Hecht SM. Expanding the Scope of Protein Synthesis Using Modified Ribosomes. J Am Chem Soc. 2019; 141: 6430-6447.
91. Melnikov SV, Khabibullina NF, Mairhofer E, Vargas-Rodriguez O, Reynolds NM, et al. Mechanistic insights into the slow peptide bond formation with D-amino acids in the ribosomal active site. Nucleic Acids Res. 2019; 47: 2089-2100.
92. Dedkova LM, Fahmi NE, Golovine SY, Hecht SM. Enhanced D-amino acid incorporation into protein by modified ribosomes. J Am Chem Soc. 2003; 125: 6616-6617.
93. Dedkova LM, Fahmi NE, Golovine SY, Hecht SM. Construction of modified ribosomes for incorporation of D-amino acids into proteins. Biochemistry. 2006; 45: 15541-15551.
94. Maini R, Nguyen DT, Chen S, Dedkova LM, Chowdhury SR, et al. Incorporation of beta-amino acids into dihydrofolate reductase by ribosomes having modifications in the peptidyltransferase center. Bioorg Med Chem. 2013; 21: 1088-1096.
95. Melo Czekster C, Robertson WE, Walker AS, Soll D, Schepartz A. In Vivo Biosynthesis of a beta-Amino Acid-Containing Protein. J Am Chem Soc. 2016; 138: 5194-5197.
96. Thyer R, Filipovska A, Rackham O. Engineered rRNA enhances the efficiency of selenocysteine incorporation during translation. J Am Chem Soc. 2013; 135: 2-5.
97. Wang K, Neumann H, Peak-Chew SY, Chin JW. Evolved orthogonal ribosomes enhance the efficiency of synthetic
genetic code expansion. Nat Biotechnol. 2007; 25: 770-777.
98. Neumann H, Wang K, Davis L, Garcia-Alai M, Chin JW. Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome. Nature. 2010; 464: 441-444.
99. Polycarpo CR, Herring S, Berube A, Wood JL, Soll D, et al. Pyrrolysine analogues as substrates for pyrrolysyl-tRNA synthetase. FEBS Lett. 2006; 580: 6695-6700.
100. Katayama H, Nozawa K, Nureki O, Nakahara Y, Hojo H. Pyrrolysine analogs as substrates for bacterial pyrrolysyl-tRNA synthetase in vitro and in vivo. Biosci Biotechnol Biochem. 2012; 76: 205-208.
101. Wang YS, Fang X, Wallace AL, Wu B, Liu WR. A rationally designed pyrrolysyl-tRNA synthetase mutant with a broad substrate spectrum. J Am Chem Soc. 2012; 134: 2950-2953.
102. Ikeda-Boku A, Ohno S, Hibino Y, Yokogawa T, Hayashi N, et al. A simple system for expression of proteins containing 3-azidotyrosine at a pre-determined site in Escherichia coli. J Biochem. 2013; 153: 317-326.
103. Kwon I, Lim SI. Tailoring the substrate specificity of yeast phenylalanyl-tRNA synthetase toward a phenylalanine analog using multiple-site-specific incorporation. ACS Synth Biol. 2015; 4: 634-643.
104. Chatterjee A, Xiao H, Yang PY, Soundararajan G, Schultz PG. A tryptophanyl-tRNA synthetase/tRNA pair for unnatural amino acid mutagenesis in E. coli. Angew Chem Int Ed Engl. 2013; 52: 5106-5109.
105. Chatterjee A, Xiao H, Schultz PG. Evolution of multiple, mutually orthogonal prolyl-tRNA synthetase/tRNA pairs for unnatural amino acid mutagenesis in Escherichia coli. Proc Natl Acad Sci U S A. 2012; 109: 14841-14846.
106. O'Donoghue P, Prat L, Heinemann IU, Ling J, Odoi K, et al. Near-cognate suppression of amber,opal and quadruplet codons competes with aminoacyl-tRNA Pyl for genetic code expansion. FEBS Lett. 2012; 586: 3931-3937.
107. Esvelt KM, Carlson JC, Liu DR. A system for the continuous directed evolution of biomolecules. Nature. 2011; 472: 499-503.
circuits by compartmentalized partnered replication. Nat Biotechnol. 2014; 32: 97-101.

109. Zhang MS, Brunner SF, Huguenin-Desot N, Liang AD, Schmied WH, et al. Biosynthesis and genetic encoding of phosphothreonine through parallel selection and deep sequencing. Nat Methods. 2017; 14: 729-736.

110. Cervettini D, Tang S, Fried SD, Willis JCW, Funke LFH, et al. Rapid discovery and evolution of orthogonal aminoacyl-tRNA synthetase-tRNA pairs. Nat Biotechnol. 2020; 38: 989-999.

111. Bryson DI, Fan C, Guo LT, Miller C, Soll D, et al. Continuous directed evolution of aminoacyl-tRNA synthetases. Nat Chem Biol. 2017; 13: 1253-1260.

112. Amiram M, Haimovich AD, Fan C, Wang YS, Aerni HR, et al. Evolution of translation machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids. Nat Biotechnol. 2015; 33:1272-1279.

113. Oki K, Sakamoto K, Kobayashi T, Sasaki HM, Yokoyama S. Transplantation of a tyrosine editing domain into a tyrosyl-tRNA synthetase variant enhances its specificity for a tyrosine analog. Proc Natl Acad Sci U S A. 2008; 105: 13298-13303.

114. Urbanek A, Morató A, Allemand F, Delaforge E, Fournet A, et al. A General Strategy to Access Structural Information at Atomic Resolution in Polyglutamine Homorepeats. Angewandte Chemie. 2018; 130: 3660-3663.

115. Murakami H, Ohta A, Ashigai H, Suga H. A highly flexible tRNA acylation method for non-natural polypeptide synthesis. Nat Methods. 2006; 3: 357-359.

116. Ninomiya K, Kurita T, Hohsaka T, Sisido M. Facile aminoacylation of pdCpA dinucleotide with a nonnatural amino acid in cationic micelle. Chem Commun (Camb). 2003; 2242-2243.

117. Ohshiro Y, Nakajima E, Goto Y, Fuse S, Takahashi T, et al. Ribosomal synthesis of backbone-macrocyclic peptides containing gamma-amino acids. Chembiochem. 2011; 12: 1183-1187.

118. Kawakami T, Ishizawa T, Murakami H. Extensive reprogramming of the genetic code for genetically encoded synthesis of highly N-alkylated polycyclic peptidomimetics.
119. Kwiatkowski M, Wang J, Forster AC. Facile synthesis of N-acyl-aminoacyl-pCpA for preparation of mischarged fully ribo tRNA. Bioconjug Chem. 2014; 25: 2086-2091.

120. Kawakami T, Ogawa K, Hatta T, Goshima N, Natsume T. Directed Evolution of a Cyclized Peptoid-Peptide Chimera against a Cell-Free Expressed Protein and Proteomic Profiling of the Interacting Proteins to Create a Protein-Protein Interaction Inhibitor. ACS Chem Biol. 2016; 11:1569-1577.

121. Rogers JM, Kwon S, Dawson SJ, Mandal PK, Suga H, et al. Ribosomal synthesis and folding of peptide-helical aromatic foldamer hybrids. Nat Chem. 2018; 10: 405-412.

122. Bashiruddin NK, Suga H. Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies. Current opinion in chemical biology. 2015; 24: 131-138.

123. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res. 2008; 41: 1331-1342.

124. Baeriswyl V, Heinis C. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. Protein Eng Des Sel. 2013; 26: 81-89.

125. Gillies ER, Deiss F, Staedel C, Schmitter JM, Huc I. Development and Biological Assessment of Fully Water-soluble Helical Aromatic Amide Foldamers. Angewandte Chemie International Edition. 2007; 46: 4081-4084.

126. Katoh T, Suga H. Engineering Translation Components Improve Incorporation of Exotic Amino Acids. Int J Mol Sci. 2019; 20.

127. Urbanek A, Elena-Real CA, Popovic M, Morato A, Fournet A, et al. Site-Specific Isotopic Labeling (SSIL): Access to High-Resolution Structural and Dynamic Information in Low-Complexity Proteins. Chembiochem. 2020; 21: 769-775.

128. Fahnestock S, Rich A. Ribosome-catalyzed polyester formation. Science. 1971; 173: 340-343.

129. Merryman C, Green R. Transformation of aminoacyl tRNAs for the in vitro selection of "drug-like" molecules. Chem Biol. 2004; 11: 575-582.
130. Fahmi NE, Dedkova L, Wang B, Golovine S, Hecht SM. Site-specific incorporation of glycosylated serine and tyrosine derivatives into proteins. J Am Chem Soc. 2007; 129: 3586-3597.
131. Iijima I, Hohsaka T. Position-specific incorporation of fluorescent non-natural amino acids into maltose-binding protein for detection of ligand binding by FRET and fluorescence quenching. Chembiochem. 2009; 10: 999-1006.
132. Hecht SM, Alford BL, Kuroda Y, Kitano S. "Chemical aminoacylation" of tRNA's. J Biol Chem. 1978; 253: 4517-4520.
133. Heckler TG, Chang LH, Zama Y, Naka T, Chorghade MS, et al. T4 RNA ligase mediated preparation of novel "chemically misacylated" tRNAPheS. Biochemistry. 1984; 23: 1468-1473.
134. Noren CJ, Anthony-Cahill SJ, Griffith MC, Schultz PG. A general method for site-specific incorporation of unnatural amino acids into proteins. Science. 1989; 244: 182-188.
135. Lodder M, Wang B, Hecht SM. The N-pentenoyl protecting group for aminoacyl-tRNAs. Methods. 2005; 36: 245-251.
136. Yamanaka K, Nakata H, Hohsaka T, Sisido M. Efficient synthesis of nonnatural mutants in Escherichia coli S30 in vitro protein synthesizing system. Journal of Bioscience and Bioengineering. 2004; 97: 395-399.
137. Choudhury AK, Golovine SY, Dedkova LM, Hecht SM. Synthesis of proteins containing modified arginine residues. Biochemistry. 2007; 46: 4066-4076.
138. Breuillard C, Bonhomme S, Couderc R, Cynober L, De Bandt JP. In vitro anti-inflammatory effects of citrulline on peritoneal macrophages in Zucker diabetic fatty rats. Br J Nutr. 2015; 113: 120-124.
139. Peuker S, Andersson H, Gustavsson E, Maiti KS, Kania R, et al. Efficient Isotope Editing of Proteins for Site-Directed Vibrational Spectroscopy. J Am Chem Soc. 2016; 138: 2312-2318.
140. Goto Y, Katoh T, Suga H. Flexizymes for genetic code reprogramming. Nat Protoc. 2011; 6: 779-790.
141. Xiao H, Murakami H, Suga H, Ferre-D'Amare AR. Structural basis of specific tRNA aminoacylation by a small
142. Morimoto J, Hayashi Y, Iwasaki K, Suga H. Flexizymes: their evolutionary history and the origin of catalytic function. Acc Chem Res. 2011; 44: 1359-1368.

143. Niwa N, Yamagishi Y, Murakami H, Suga H. A flexizyme that selectively charges amino acids activated by a water-friendly leaving group. Bioorg Med Chem Lett. 2009; 19: 3892-3894.

144. Passiourea T, Suga H. Flexizyme-mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery. Chemistry. 2013; 19: 6530-6536.

145. Lee J, Schwieter KE, Watkins AM, Kim DS, Yu H, et al. Expanding the limits of the second genetic code with ribozymes. Nat Commun. 2019; 10: 5097.

146. Fujino T, Goto Y, Suga H, Murakami H. Reevaluation of the D-amino acid compatibility with the elongation event in translation. J Am Chem Soc. 2013; 135: 1830-1837.

147. Fujino T, Goto Y, Suga H, Murakami H. Ribosomal Synthesis of Peptides with Multiple β-Amino Acids. Journal of the American Chemical Society. 2016; 138: 1962-1969.

148. Suga H. Max-Bergmann award lecture: A RapID way to discover bioactive nonstandard peptides assisted by the flexizyme and FIT systems. J Pept Sci. 2018; 24.

149. Rothman DM, Petersson EJ, Vazquez ME, Brandt GS, Dougherty DA, et al. Caged phosphoproteins. J Am Chem Soc. 2005; 127: 846-847.

150. Zhu P, Gafken PR, Mehl RA, Cooley RB. A Highly Versatile Expression System for the Production of Multiply Phosphorylated Proteins. ACS Chemical Biology. 2019; 14: 1564-1572.

151. Xiao H, Peters FB, Yang PY, Reed S, Chittuluru JR, et al. Genetic incorporation of histidine derivatives using an engineered pyrrolysyl-tRNA synthetase. ACS Chem Biol. 2014; 9: 1092-1096.

152. Gan F, Liu R, Wang F, Schultz PG. Functional Replacement of Histidine in Proteins To Generate Noncanonical Amino Acid Dependent Organisms. J Am Chem Soc. 2018; 140: 3829-3832.

153. Ortmayer M, Fisher K, Basran J, Wolde-Michael EM, Heyes DJ, et al. Rewiring the “Push-Pull” Catalytic
Machinery of a Heme Enzyme Using an Expanded Genetic Code. ACS Catalysis. 2020; 10: 2735-2746.

154. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev. 2000; 64: 435-459.

155. Wakamori M, Fujii Y, Suka N, Shirouzu M, Sakamoto K, et al. Intra- and inter-nucleosomal interactions of the histone H4 tail revealed with a human nucleosome core particle with genetically-incorporated H4 tetra-acetylation. Sci Rep. 2015; 5: 17204.

156. Xiong H, Reynolds NM, Fan C, Englert M, Hoyer D, et al. Dual Genetic Encoding of Acetyl-lysine and Non-deacetylatable Thioacetyl-lysine Mediated by Flexizyme. Angew Chem Int Ed Engl. 2016; 55: 4083-4086.

157. Yanagisawa T, Takahashi M, Mukai T, Sato S, Wakamori M, et al. Multiple Site-Specific Installations of Nε-Monomethyl-L-Lysine into Histone Proteins by Cell-Based and Cell-Free Protein Synthesis. ChemBioChem. 2014; 15: 1830-1838.